Repligen Corporation

RGEN·NasdaqGS·Healthcare
Compare
172.51−1.37 (−0.79%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours172.510.00 (0.00%)Oct 12, 4:00 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close173.88
Open171.73
Day range169.90173.82
52-week range100.99198.87
Off day high−0.75%
Off 52-week high−13.25%
Volume899.60K
Avg. volume (3M)1.19M
Market cap10.95B
EPS (TTM)0.7300
Forward P/E65.27
P/E ratio (TTM)236.32
Dividend yield—
Beta (5Y)1.08
Shares outstanding63.49M
Short interest13.47% of float
Earnings dateJul 28, 2026
Analyst target196.70
Profit margin5.29%

Against its peers

Compare in full ›
RGEN BLFS AVTR AZTA NNNN HBIO
Market cap 10.95B 1.89B 10.48B 1.65B 193.56M 37.51M
P/E (TTM) 236.3 39.0 — — 29.4 —
Forward P/E 65.3 117.0 17.7 68.4 — 12.8
Price/book 4.6 4.5 1.9 1.1 6.4 5.1
Dividend yield — — — — — —
1-year change +16.96% +39.59% +11.36% +23.43% −83.09% +96.19%
Today −0.79% 0.00% −1.15% +0.13% −5.36% 0.00%

The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.

Latest news

All RGEN news ›
Stock Titan·Negative

Repligen: Abigail P. Johnson reports 13% stake

One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. Stock Titan - [SCHEDULE 13G/A] REPLIGEN CORP Amended Passive Investment Disclosure Repligen: Abigail P. Johnson reports 13% stake FMR reported sole…

@StockTitan_net·

Repligen CEO sells 4,202 shares at $190 per share

Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO sells 4,202 shares at $190 per share Both reported sales were made under a…

@StockTitan_net·Positive

Repligen completes BioLife Solutions acquisition

Repligen said BioLife will benefit from its broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships. At closing, shares issuable under BioLife options, RSUs, PSUs and RSAs…

@StockTitan_net·

Repligen: Olivier Loeillot proposes $238K share sale

1,333 shares vested October 2 are proposed for sale at Repligen (NASDAQ: RGEN). Stock Titan Repligen: Olivier Loeillot proposes $238K share sale The notice identifies restricted stock vesting on October 2, 2026, as the source of the shares…

@StockTitan_net·

Repligen CEO has 1,248 shares withheld for taxes

Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO has 1,248 shares withheld for taxes The withholding satisfied tax…

@StockTitan_net·

Recursion director proposes $242K share sale

A 50,000-share sale is proposed by director Blake C. Borgeson at Recursion (RXRX). Stock Titan Recursion director proposes $242K share sale The notice also lists three Class A sales by the director from July 7 through September 1, 2026.…

@_AlphaStreet·Negative

Repligen Drops 5.3% Amid Sector-Wide Selling - Alphastreet

Sector selloff drags Repligen lower. Repligen Corporation (NASDAQ:RGEN) shares tumbled 5.3% on Thursday, October 01, 2026, closing at $182.00 as a broad dow... The post Repligen Drops 5.3% Amid Sector-Wide Selling first appeared on…

From articles in the 4Search news index.

In the news

11mentions in 30 days
9with it in the headline
Mixedsentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.